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The complexity of parturition makes preterm birth prevention a problem without a simple solution. Increased mTORC1 activity is linked to premature decidual senescence, a significant contributor to preterm birth that leads to maternal and neonatal morbidity and mortality. Deng et al. [1] investigated metformin or tesveratrol as possible preventative options that alter the relationship between mTORC1 and pAMPK signaling pathways.
Investigators generated a mouse model with conditional uterine deletion of p53 (p53 d/d )-long considered the guardian of the genome-and observed increased incidence of spontaneous preterm birth after application of a small dose of an inflammatory stimulus, lipopolysaccharide (LPS). This spike was tied to elevated mTORC1 signaling. Pairing rapamycin, an mTORC1 inhibitor, with a single dose of progesterone administered to p53 d/d dams substantially reduced spontaneous and LPS-induced preterm birth. The same dose of LPS in control mice resulted in no preterm births, nor any apparent adverse effects on fetus or mother.
These experiments led investigators to seek alternative remedies resulting in higher efficacy and fewer side effects. They identified metformin (an antidiabetic drug) and resveratrol (an antioxidant and antiaging component found in grape seed extracts) as compounds that reduced spontaneous and inflammation-induced preterm birth in the p53 d/d mouse model by activating AMPK signaling and inhibiting mTORC1 signaling. The results showed the two pathways to be inversely connected.
Investigators further noted that sestrin 2, a scaffolding protein, triggered AMPK activation and dampened mTORC1 signaling in the mouse model. Genotoxic stress induces the release of sestrins, which regulate accumulation of metabolically active oxidants that advance cellular aging. Investigators tested sestrin 2 levels in p53 d/d mouse deciduae and found them to be significantly lower compared to controls. Moreover, treating control and conditionally deleted mice with metformin increased sestrin 2 levels in both, while also decreasing pS6 levels (mTORC1 signaling). Deng et. al performed further experiments using human decidual cells to confirm the presence of the AMPK-mTORC1 inverse relationship and the involvement of sestrin 2 as an AMPK modulator. Treating these cells with metformin or resveratrol increased AMPK signaling while decreasing mTORC1, similar to the effects observed in mouse decidual cells.
This study illuminates the coordinated transcriptional and signaling pathways that determine mechanisms of parturition timing, with significant implications for the study of preterm birth. These findings could lead to new therapies or the repurposing of preexisting drugs to limit incidences of preterm birth.
